Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV

References

• Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, Beary H, Hayes D, Frankel SS, Birx DL, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207-10. https://doi.org/10.1038/72318. PMID:10655111
   PubMed Web of Science ®Google Scholar
• Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, Ketas T, Marx PA, Klasse PJ, Burton DR, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med. 2003;9(3):343-6. https://doi.org/10.1038/nm833. PMID:12579198
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. Plos Pathog. 2009;5(5):e1000433. https://doi.org/10.1371/journal.ppat.1000433. PMID:19436712
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Jaworski JP, Epson E, Matsuda K, Pandey S, Kahl C, Reed J, Sutton WF, Hammond KB, Cheever TA, et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med. 2016;22(4):362-8. https://doi.org/10.1038/nm.4063. PMID:26998834
   PubMed Web of Science ®Google Scholar
• Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, Stephenson KE, Chang HW, Shekhar K, Gupta S, et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature. 2013;503(7475):224-8. PMID:24172905
   PubMed Web of Science ®Google Scholar
• Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, Piaskowski SM, Bergman Z, Watkins DI, Poignard P, et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci USA. 2012;109(46):18921-5. https://doi.org/10.1073/pnas.1214785109. PMID:23100539
   PubMed Web of Science ®Google Scholar
• Shingai M, Nishimura Y, Klein F, Mouquet H, Donau OK, Plishka R, Buckler-White A, Seaman M, Piatak M Jr, Lifson JD, et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature. 2013;503(7475):277-80. PMID:24172896
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487-91. https://doi.org/10.1038/nature14411. PMID:25855300
   PubMed Web of Science ®Google Scholar
• Caskey M, Klein F, Nussenzweig MC: Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy. N Engl J Med. 2016;375(21):2019-21. https://doi.org/10.1056/NEJMp1613362. PMID:27959740
   PubMed Web of Science ®Google Scholar
• Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Translat Med. 2015;7(319):319ra206. https://doi.org/10.1126/scitranslmed.aad5752
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, et al. Safety, Pharmacokinetics, and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults. Clin Exp Immunol. 2015;182(3):289-301. https://doi.org/10.1111/cei.12692. PMID:26332605
   PubMed Web of Science ®Google Scholar
• Kelley B: Industrialization of mAb production technology The bioprocessing industry at a crossroads. Mabs. 2009;1(5):443-52. https://doi.org/10.4161/mabs.1.5.9448. PMID:20065641
   PubMed Web of Science ®Google Scholar
• Felo M, Christensen B, Higgins J: Process cost and facility considerations in the selection of primary cell culture clarification technology. Biotechnol Prog. 2013;29(5):1239-45. https://doi.org/10.1002/btpr.1776. PMID:23847160
   PubMed Web of Science ®Google Scholar
• Frenzel A, Hust M, Schirrmann T. Expression of recombinant antibodies. Front Immunol. 2013;4:217. https://doi.org/10.3389/fimmu.2013.00217. PMID:23908655
   PubMed Web of Science ®Google Scholar
• Schirrmann T, Al-Halabi L, Dubel S, Hust M: Production systems for recombinant antibodies. Front Biosci. 2008;13:4576-94. https://doi.org/10.2741/3024. PMID:18508530
   PubMed Web of Science ®Google Scholar
• Virdi V, Depicker A. Role of plant expression systems in antibody production for passive immunization. Int J Dev Biol. 2013;57(6-8):587-93. https://doi.org/10.1387/ijdb.130266ad. PMID:24166441
   PubMed Web of Science ®Google Scholar
• Buckholz RG, Gleeson MA: Yeast systems for the commercial production of heterologous proteins. Biotechnology. 1991;9(11):1067-72. https://doi.org/10.1038/nbt1191-1067. PMID:1367623
   PubMed Web of Science ®Google Scholar
• Seo MJ, Jeong KJ, Leysath CE, Ellington AD, Iverson BL, Georgiou G: Engineering antibody fragments to fold in the absence of disulfide bonds. Prot Sci 2009;18(2):259-267. https://doi.org/10.1002/pro.31
   PubMed Web of Science ®Google Scholar
• Huston JS, Levinson D, Mudgett-Hunter M, Tai MS, Novotný J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci USA . 1988;85(16):5879-83. https://doi.org/10.1073/pnas.85.16.5879. PMID:3045807
   PubMed Web of Science ®Google Scholar
• de Marco A. Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact 2009;8:26. https://doi.org/10.1186/1475-2859-8-26. PMID:19442264
   PubMed Web of Science ®Google Scholar
• Lee YJ, Jeong KJ. Challenges to production of antibodies in bacteria and yeast. J Biosci Bioeng. 2015;120(5):483-90. https://doi.org/10.1016/j.jbiosc.2015.03.009. PMID:25912450
   PubMed Web of Science ®Google Scholar
• Martineau P, Jones P, Winter G: Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol. 1998;280(1):117-27. https://doi.org/10.1006/jmbi.1998.1840. PMID:9653035
   PubMed Web of Science ®Google Scholar
• Proba K, Worn A, Honegger A, Pluckthun A: Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol. 1998;275(2):245-53. https://doi.org/10.1006/jmbi.1997.1457. PMID:9466907
   PubMed Web of Science ®Google Scholar
• Wang LX, Mellon M, Bowder D, Quinn M, Shea D, Wood C, Xiang SH. Escherichia coli surface display of single-chain antibody VRC01 against HIV-1 infection. Virology. 2015;475:179-86. https://doi.org/10.1016/j.virol.2014.11.018. PMID:25482819
   PubMed Web of Science ®Google Scholar
• Maruta Y, Kuwata T, Tanaka K, Alam M, Valdez KP, Egami Y, Suwa Y, Morioka H, Matsushita S. Cross-neutralization activity of single-chain variable fragment (scFv) derived from anti-V3 monoclonal antibodies mediated by post-attachment binding. Jpn J Infect Dis. 2016;69(5):395-404. https://doi.org/10.7883/yoken.JJID.2015.667. PMID:26902223
   PubMed Web of Science ®Google Scholar
• Beasley MD, Niven KP, Winnall WR, Kiefel BR: Bacterial cytoplasmic display platform Retained Display (ReD) identifies stable human germline antibody frameworks. Biotechnol J. 2015;10(5):783-9. https://doi.org/10.1002/biot.201400560. PMID:25712138
   PubMed Web of Science ®Google Scholar
• Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A: The intracellular antibody capture technology (IACT): Towards a consensus sequence for intracellular antibodies. J Mol Biol. 2002;317(1):73-83. https://doi.org/10.1006/jmbi.2002.5392. PMID:11916379
   PubMed Web of Science ®Google Scholar
• Tse E, Lobato MN, Forster A, Tanaka T, Chung GT, Rabbitts TH: Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J Mol Biol. 2002;317(1):85-94. https://doi.org/10.1006/jmbi.2002.5403. PMID:11916380
   PubMed Web of Science ®Google Scholar
• Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406-12. https://doi.org/10.1038/nature11544. PMID:23151583
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scharf L, Euler Z, Liu Y, Eden C, Scheid JF, Halper-Stromberg A, Gnanapragasam PN, Spencer DI, Seaman MS, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci USA. 2012;109(47):E3268-77. https://doi.org/10.1073/pnas.1217207109. PMID:23115339
   PubMed Web of Science ®Google Scholar
• Kufer P, Lutterbuse R, Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol. 2004;22(5):238-44. https://doi.org/10.1016/j.tibtech.2004.03.006. PMID:15109810
   PubMed Web of Science ®Google Scholar
• Chen M, Wen K, Tao XQ, Xie J, Wang L, Li Y, Ding S, Jiang H. Cloning, expression, purification and characterization of a bispecific single-chain diabody against fluoroquinolones and sulfonamides in Escherichia coli. Protein Expr Purif. 2014;100:19-25. https://doi.org/10.1016/j.pep.2014.04.015. PMID:24816423
   PubMed Web of Science ®Google Scholar
• Huang BC, Davern S, Kennel SJ: Mono and bivalent binding of a scFv and covalent diabody to murine laminin-1 using radioiodinated proteins and SPR measurements: Effects on tissue retention in vivo. J Immunol Meth. 2006;313(1-2):149-60. https://doi.org/10.1016/j.jim.2006.04.006
   PubMed Web of Science ®Google Scholar
• Winnall WR, Beasley MD, Center RJ, Parsons MS, Kiefel BR, Kent SJ: The maturation of antibody technology for the HIV epidemic. Immunol Cell Biol. 2014;92(7):570-7. https://doi.org/10.1038/icb.2014.35. PMID:24797582
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: Natural single-domain antibodies. Annu Rev Biochem 2013;82:775-97. https://doi.org/10.1146/annurev-biochem-063011-092449. PMID:23495938
   PubMed Web of Science ®Google Scholar
• Forsman A, Beirnaert E, Aasa-Chapman MM, et al.: Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virology. 2008;82(24):12069-81. https://doi.org/10.1128/JVI.01379-08. PMID:18842738
   PubMed Web of Science ®Google Scholar
• Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, Kwon YD, Scheid JF, Shi W, Xu L, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811-7. https://doi.org/10.1126/science.1192819. PMID:20616231
   PubMed Web of Science ®Google Scholar
• Rozak DA, Orban J, Bryan PN. G148-GA3: A streptococcal virulence module with atypical thermodynamics of folding optimally binds human serum albumin at physiological temperatures. Biochim Biophys Acta. 2005;1753(2):226-33. https://doi.org/10.1016/j.bbapap.2005.10.005. PMID:16290081
   PubMed Web of Science ®Google Scholar
• Sok D, Laserson U, Laserson J, Liu Y, Vigneault F, Julien JP, Briney B, Ramos A, Saye KF, Le K, et al. The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 2013;9(11):e1003754. https://doi.org/10.1371/journal.ppat.1003754. PMID:24278016
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zapata G, Shalaby R, Snedecor B, Chen H, Carter P: High level secretion of a humanized bispecific diabody from Escherichia coli. Biotechnology. 1996;14(2):192-6. PMID:9636323
   PubMed Web of Science ®Google Scholar
• Rutebemberwa A, Bess JW, Brown B, Arroyo M, Eller M, Slike B, Polonis V, McCutchan F, Currier JR, Birx D, et al. Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses. AIDS Res Hum Retroviruses. 2007;23(4):532-42. https://doi.org/10.1089/aid.2006.0136. PMID:17506610
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70. https://doi.org/10.1038/nature10373. PMID:21849977
   PubMed Web of Science ®Google Scholar
• Derdeyn CA, Moore PL, Morris L. Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS. 2014;9(3):210-16. https://doi.org/10.1097/COH.0000000000000057. PMID:24662931
   PubMed Web of Science ®Google Scholar
• Georgiev IS, Rudicell RS, Saunders KO, Shi W, Kirys T, McKee K, O'Dell S, Chuang GY, Yang ZY, Ofek G, et al. Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J Immunol. 2014;192(3):1100-06. https://doi.org/10.4049/jimmunol.1302515. PMID:24391217
   PubMed Web of Science ®Google Scholar
• Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, West AP Jr, Bjorkman PJ, et al. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell. 2015;160(3):433-46. https://doi.org/10.1016/j.cell.2015.01.016. PMID:25635457
   PubMed Web of Science ®Google Scholar
• Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Prot Immunol. 2005; Chapter 12:Unit 12 11.
   PubMedGoogle Scholar